MDS 2023 | Overcoming venetoclax resistance in myeloid malignancies with selective inhibition of MCL1
Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN, discusses mechanisms of resistance to venetoclax in patients with myeloid malignancies, highlighting approaches to manage BCL2 resistance with selective MCL1 inhibition. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Ryvu: Consultancy, Current equity holder in publicly-traded company, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Other: serves on Data and Safety Monitoring Boards; TG Therapeutics: Research Funding; Incyte: Research Funding; Astex: Research Funding; Takeda: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Taiho: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Geron: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Forma: Consultancy; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: serves on Data and Safety Monitoring Boards; ALX Oncology: Research Funding.
